J.P. Kleim
Clinical Virology Unit
Glaxo Wellcome
Stevenage
Herts SG1 2NY
United Kingdom
Name/email consistency: high
- Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group. Kleim, J.P., Winters, M., Dunkler, A., Suarez, J.R., Riess, G., Winkler, I., Balzarini, J., Oette, D., Merigan, T.C. J. Infect. Dis. (1999)